Novartis’s BLA has been accepted by US FDA & EMA for Kymriah (Tisagenlecleucel) to treat patients with relapsed or refractory follicular lymphoma.

by admin
0 comment

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy
WP2Social Auto Publish Powered By :